FDA Approves Gilead's Biannual Injection for HIV Prevention in the US
The FDA has approved Gilead's groundbreaking twice-yearly injection to prevent HIV, offering a powerful new tool in the fight against the virus with over 99.9% efficacy demonstrated in clinical trials.
On June 18, 2025, the U.S. Food and Drug Administration (FDA) approved Gilead Sciences' innovative twice-yearly injection designed to prevent HIV transmission. This landmark approval marks a significant advancement in HIV prevention strategies, providing a long-lasting alternative to daily oral medications. The injectable treatment, marketed as Yeztugo and containing the drug lenacapavir, has demonstrated in clinical trials the ability to reduce the risk of HIV infection by over 99.9% in adults and adolescents, effectively functioning like a powerful vaccine.
Pre-exposure prophylaxis (PrEP) medications have been available for over ten years, mainly in pill form requiring daily intake. However, adherence challenges have limited their impact on reducing global infection rates. This new injectable offers a promising solution by minimizing the need for frequent dosing, which could enhance compliance and broadening prevention efforts.
Despite the excitement surrounding this development, concerns about accessibility remain. Although Gilead has not announced official pricing, analysts estimate the US launch price could reach up to $25,000 annually. HIV activists are calling for the price to be significantly lowered—around $25 per year—to ensure widespread access and help end the HIV pandemic.
The approval comes at a time when U.S. funding for HIV treatment and prevention programs has been cut by the current administration, both domestically and internationally, raising questions about equitable access to this promising new tool. Still, health experts believe that this innovation could transform HIV prevention, reducing new infections and saving lives.
Source: https://medicalxpress.com/news/2025-06-gilead-yearly-hiv.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Innovative Medication Vending Machines Introduced at Advocate Health Care in Chicago
Advocate Health Care has launched innovative vending machines in Chicago to dispense prescription medications, improving access and convenience for patients, especially in underserved areas.
Innovative PET Tracer Enhances Detection of Invasive Mold Infections in Cancer and Transplant Patients
A new PET radiotracer, 18F-FDS, offers precise, non-invasive detection of invasive mold infections in immunocompromised patients, improving diagnosis and treatment outcomes.
Enhancing Dementia Detection through Artificial Intelligence
Innovative use of artificial intelligence, including natural language processing, is transforming dementia detection in hospitals, enabling earlier and more accurate diagnosis through analysis of electronic health records.
Experts Urge Action to Address Conflicts of Interest to Safeguard Public Health
A University of Bath study highlights the urgent need to tackle conflicts of interest with industries harming public health, to ensure effective health policies and sustained healthcare systems.